Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Watch a 40% Decline Disappear

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

The greatest thing going for Johnson & Johnson (NYSE: JNJ  ) is its diversity in product offerings.

Recall after recall led to U.S. sales of over-the-counter drugs and nutritional products plunging 40% in the third quarter. That would crush most companies. Johnson & Johnson? It just laughs it off.

The company sells other consumer products, so overall U.S. consumer sales were down just 24.5%. And Johnson & Johnson sells more consumer products overseas than it does stateside, so the entire consumer division was down just 10.6%. Add in sales of drugs and medical devices to complete the diversification magic, and total sales fell a measly 0.7%.

That's not to say everything is perfect with Johnson & Johnson. Even if you add back in the $300 million or so that OTC and nutritional products dropped in the third quarter, sales are only up 1.3%; that's nothing to get excited about.

The lackluster performance can be traced back to medical devices, Johnson & Johnson's largest division. Management blamed the paltry 1.3% sales increase there on the economy. While health care is somewhat recession-proof, patients often delay elective procedures, especially if they're out of work and don't have health insurance. We'll have to wait until Stryker (NYSE: SYK  ) , Zimmer (NYSE: ZMH  ) , and Smith & Nephew (NYSE: SNN  ) report to find out whether the theory is right or not.

Prescription drugs were the one bright spot, especially since the company had been dealing with difficult year-over-year comparisons after losing drugs to generic competition. Overall, sales of prescription drugs were up 4.7%, thanks in large part to sales of anti-inflammatory, Remicade, which increased 18.6%. Most of that increase was from exports to outside the U.S., where Merck (NYSE: MRK  ) sells the drug.

I'm inclined to chalk this up as a could-have-been-worse quarter. If you're a long-term shareholder, the exact timing of the turnaround in the consumer segment and the return of elective procedures shouldn't matter that much. Investors should keep an eye on the company, though, to ensure things don't get worse.

20% returns? Jeremy Phillips says to ignore them.

Motley Fool Options has recommended a diagonal call position on Johnson & Johnson, which is a Motley Fool Income Investor recommendation. Stryker is a Motley Fool Inside Value recommendation. Try any of our Foolish newsletter services free for 30 days.

True to its name, The Motley Fool is made up of a motley assortment of writers and analysts, each with a unique perspective; sometimes we agree, sometimes we disagree, but we all believe in the power of learning from each other through our Foolish community.

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. The Fool owns shares of Johnson & Johnson and has a disclosure policy.

Read/Post Comments (0) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1337084, ~/Articles/ArticleHandler.aspx, 10/27/2016 5:19:05 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 8 hours ago Sponsored by:
DOW 18,199.33 30.06 0.17%
S&P 500 2,139.43 -3.73 -0.17%
NASD 5,250.27 -33.13 -0.63%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/26/2016 4:00 PM
JNJ $114.56 Up +0.60 +0.53%
Johnson and Johnso… CAPS Rating: ****
MRK $60.87 Down -1.08 -1.74%
Merck and Co. CAPS Rating: ****
SNN $29.51 Down -0.34 -1.14%
Smith and Nephew CAPS Rating: ****
SYK $109.89 Down -3.30 -2.92%
Stryker CAPS Rating: *****
ZMH.DL $0.00 Down +0.00 +0.00%
Zimmer Holdings CAPS Rating: ****